• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Further Analysis of ARRIVE: What are the Perinatal Outcomes Associated with Expectant Management in Low-Risk, Nulliparous Individuals?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Tita et al. (Obstetrics & Gynecology, 2021) compared risks of maternal and perinatal outcomes by completed week of gestation from 39 weeks in low-risk nulliparous patients undergoing expectant management

METHODS:

  • Secondary analysis of the ARRIVE trial
    • Multicenter RCT
  • Participants
    • Low risk nulliparous pregnant women
    • Non-anomalous neonates
    • Women who were randomized to the expectant management group and attained 39w0d weeks of gestation in the original ARRIVE trial
  • Exposures
    • 39 weeks gestation (39w0d to 39w6d)  
    • 40 weeks gestation (40w0d to 40w6d)
    • 41 to 42 weeks gestation (41w0d to 42w2d)  
  • Data analysis
    • For multivariable analysis, P<.0125 was used to indicate statistical significance for coprimary outcomes
  • Primary outcomes
    • Cesarean delivery
    • Perinatal composite: Death | Respiratory support | 5-minute Apgar ≤3 | HIE | Seizure | Sepsis | Meconium aspiration syndrome | Birth trauma | Intracranial or subgleal hemorrhage | Hypotension requiring vasopressor support
  • Secondary outcomes
    • Maternal composite: Transfusion | Surgical intervention for PPH | ICU admission
    • Hypertensive disorders of pregnancy
    • Peripartum infection
    • Neonatal intermediate or intensive care unit admission

RESULTS:

  • 2502 participants underwent expectant management with delivery at the following weeks gestation
    • 39 weeks: 38.5%
    • 40 weeks: 44.4%
    • 41 to 42 weeks: 17.1%
  • Prevalence of medically indicated delivery
    • Overall: 37.9%
    • 39 weeks: 23.8%
    • 41 to 42 weeks: 80.3%
    • Reasons for delivery at 39 or 40 completed weeks
      • Postterm induction (at 40 completed weeks) | Hypertensive disorders of pregnancy | PROM
  • The frequency of both cesarean and the perinatal composite increased with increased gestational age at delivery
    • Cesarean (P < 0.001)
      • 39 weeks: 17.3%
      • 40 weeks: 22.0%
      • 41 to 42 weeks: 37.5%
    • Perinatal composite (P = 0.03)
      • 39 weeks: 5.1%
      • 40 weeks: 5.9%
      • 41 to 42 weeks: 8.2%
      • After adjustment, perinatal composite still remained 56% higher in the 41 to 42 group, but was not statistically significant
  • The frequency of hypertensive disorders of pregnancy decreased with increasing gestation time (P = 0.001)
    • 39 weeks: 16.4%
    • 40 weeks: 12.1%
    • 41 to 42 weeks: 10.8%
  • There was an increased risk of cesarean at 41 to 42 weeks vs 39 weeks
    • Adjusted relative risk (RR) 1.93 (95% CI, 1.61 to 2.32)
  • There was a decreased risk of hypertensive disorders of pregnancy with greater gestational age vs 39 weeks
    • 40 week: aRR 0.71 (95% CI, 0.58 to 0.88)
    • 41 to 42 weeks: aRR 0.61 (95% CI, 0.45 to 0.82)
  • None of the other outcomes were found to be significant

CONCLUSION:

  • For nulliparous women with low-risk pregnancies, expectant management after 39w0d increased the risk for cesarean and medically indicated delivery
    • There was no change in perinatal composite outcome after adjustments
  • Risks associated with stillbirth and neonatal death could not be assessed due to sample size
  • The authors conclude

Overall, these data provide important insights into the anticipated course of expectant management of low-risk nulliparous patients who would typically be candidates for elective induction of labor

The information will be useful for counseling patients regarding ongoing risks of expectant management, and optimizing shared decision making

Learn More – Primary Sources:

Maternal and Perinatal Outcomes of Expectant Management of Full-Term, Low-Risk, Nulliparous Patients

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

The ARRIVE Trial and Professional Guidance: Elective 39 Week Induction to Reduce the Risk of Cesarean Section
Induction at 41 Weeks vs Expectant Management: Results from the INDEX Trial
Low-Risk Multiparous Women: Induction of Labor at 39 Weeks or Expectant Management?
Secondary Analysis of ARRIVE RCT: The Association Between Amniotomy During Induction and Cesarean Delivery

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site